PCNA and breast carcinoma: Comparing the prognostic value of FGD3 in breast cancer with the prognostic value of genes associated with proliferation such as MKI67, PCNA, and AURKA indicates that FGD3 may offer superior disease progression metrics in all clinically relevant breast cancer subtypes (Fig 6A).